Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jop Mostert

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.
Journal of Neurology|April 8, 2014
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Mike P Wattjes, Anke Vennegoor, Jop Mostert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2007
Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosisMarcus Koch, Jop Mostert, Alexander Arutjunyan, et al.
Journal of Neurology|August 15, 2021
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2021
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 30, 2021
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MSMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
ISRN Neurology|August 29, 2013
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trialJop Mostert, Thea Heersema, Manju Mahajan, et al.
Neurology|August 11, 2021
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease SpectrumMarcus W Koch, Jop Mostert, Yinan Zhang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 25, 2022
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trialsEva Mm Strijbis, Pavle Repovic, Jop Mostert, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.
Journal of Neurology|April 8, 2014
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Mike P Wattjes, Anke Vennegoor, Jop Mostert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2007
Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosisMarcus Koch, Jop Mostert, Alexander Arutjunyan, et al.
Journal of Neurology|August 15, 2021
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2021
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 30, 2021
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MSMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
ISRN Neurology|August 29, 2013
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trialJop Mostert, Thea Heersema, Manju Mahajan, et al.
Neurology|August 11, 2021
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease SpectrumMarcus W Koch, Jop Mostert, Yinan Zhang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 25, 2022
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trialsEva Mm Strijbis, Pavle Repovic, Jop Mostert, et al.
Pageof 5